EC Microbiology

Human beings are easy to infect with different types of viruses worldwide. The risks and infections for viral-induced human morbidity and mortality varied greatly among different individuals. This phenomenon is attributed to different physiological, pathological and therapeutic selections. This article outlines this string of problems and tries to discover answers from past studies.

Keywords:Viral Infection; Diagnosis; Physiology; Therapies

1. Lu DY. “HIV/AIDS treatments, fight for a cure”. LAMBERT Academic Publishing. Ed Da-Yong.
2. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China”. New England Journal of Medicine 8 (2020): 727-733.
3. Lu DY and Lu TR. “COVID-19 research, public health and biomedical basis”. Current Drug Therapy4 (2024): 367-375.
4. Zerbato V., et al. “West Nile virus, epidemiology, prevention, clinical features, diagnosis, treatment, and open research questions”. Annals of Medicine1 (2026): 2615482.
5. Lu DY., et al. “Avian flu, pathogenesis and therapy”. Anti-Infective Agents2 (2012): 124-129.
6. Hossain T., et al. “Situation report of clinical and climatic pattern changes in dengue outbreaks in Bangladesh 2024-2025”. Journal of Current Health Science4 (2025): 231-240.
7. Lu DY., et al. “Ebola therapeutic study and future trends”. Infectious Disorders - Drug Targets 1 (2019): 17-29.
8. Lu DY and Ding J. “Sequencing the whole genome of infected human cells obtained from diseased patients-a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases”. Medical Hypotheses4 (2007): 826-827.
9. Lu DY and Ding J. “AIDS and human genome studies, from a hypothesis to systematic approaches”. Medical Hypotheses 3 (2007): 695.
10. Lu DY and Lu TR. “Viral integration into human genome, potential approaches”. EC Microbiology2 (2025): 1-2.
11. Tang DY., et al. “VISDB: a manually curated database of viral integration sites in the human genome”. Nucleic Acids Research D1 (2020): D633-D641.
12. Lu DY and Lu TR. “Possible solution for coronavirus diagnosis and treatment, viral integration into human genomes”. Journal of Lung, Pulmonary and Respiratory Research2 (2025): 49.
13. Lu DY and Lu TR. “Viral integration into human genome, hopes for breakthroughs”. Hospice and Palliative Medicine International Journal4 (2025): 90-91.
14. Lu DY., et al. “HAART in HIV/AIDS treatments, future trends”. Infectious Disorders-Drug Targets1 (2018): 15-22.
15. Subramaniam S., et al. “Therapeutic antibodies for infectious diseases, recent past, present, and future”. Biochemistry 16 (2025): 3487-3494.
16. Lu DY and Lu TR. “HIV/AIDS curability study, different approaches and drug combination”. Infectious Disorders-Drug Targets4 (2023): e170123212803.
17. Lu DY and Lu TR. “COVID-19 study: a new principle discovery”. Current Drug Therapy4 (2025): 450-457.
18. Zhao YN. “Advances in HIV research: mechanisms, transmission route, and emerging therapeutic strategies”. Highlights in Science, Engineering and Technology 123 (2024): 505-509.
19. Naqvi IA and Tazvi SNZ. “The comprehensive appraisal of COVID-19: its clinical panorama from virology till management and beyond”. Coronavirus1 (2020): 57-72.
20. Rao DV., et al. “Translational approach in emerging infectious disease treatment: an update”. Biomedical Research 12 (2017): 5678-5686.
21. Lu DY and Lu TR. “Covid-19 study, diagnostic and therapeutic transition”. Recent Advances in Anti-Infective Drug Discovery 1 (2024): 21-35.
22. Lu DY. “COVID-19 conception advances, epidemics, pathology and therapeutics”. Journal of Bacteriology and Mycology: Open Access 3 (2025): 135-139.
23. Lu DY. “COVID-19 knowledge and therapeutics, past, present and future”. Journal of Bacteriology and Mycology: Open Access 2 (2025): 110-114.